Roberta Granata
University of Milan
CancerInternal medicineRadiologySurgeryPathologyOncologyHead and neck cancerInduction chemotherapyChemotherapyHead and neck squamous-cell carcinomaCisplatinChemoradiotherapyMucositisAdenoid cystic carcinomaCetuximabPopulationLocally advancedIn patientHead and neckRadiation therapyMedicineGastroenterology
87Publications
16H-index
654Citations
Publications 87
Newest
#1Laura D. LocatiH-Index: 31
#2Donata GalbiatiH-Index: 5
Last. Lisa Licitra (University of Milan)H-Index: 67
view all 17 authors...
BACKGROUND: The treatment of patients with recurrent and/or metastatic (R/M) salivary gland adenoid cystic carcinoma (ACC) remains an unmet need. METHODS: Patients with R/M disease with a history of clinical or symptomatic disease progression within 6 months and a maximum of 1 previous line of chemotherapy or a multiple kinase inhibitor received oral lenvatinib at a dose of 24 mg/day. The primary endpoint was the objective response rate; secondary endpoints included quality of life (QOL) (accord...
6 CitationsSource
#1Ester Orlandi (University of Milan)H-Index: 22
#2Stefano Cavalieri (University of Milan)H-Index: 8
Last. Paolo Bossi (University of Brescia)H-Index: 39
view all 21 authors...
OBJECTIVE: Outcomes of locally advanced epithelial sinonasal cancers remain unsatisfactory; moreover, only limited and heterogeneous data exist on prognostic factors. METHODS: We reviewed all consecutive patients with American Joint Committee Cancer stage III to IV epithelial sinonasal cancers treated with platinum-based induction chemotherapy (IC) followed by locoregional treatment between 1996 and 2015. RESULTS: We identified 69 patients treated with a multimodal approach (IC, surgery, radioth...
6 CitationsSource
BACKGROUND: Patients with prognosis recurrent/metastatic (R/M) salivary gland carcinomas (SGCs) are poor. Activity of axitinib was demonstrated in adenoid cystic carcinoma (ACC). We tested axitinib in a larger cohort of R/M SGCs including non-ACC. METHODS: Axitinib was administered at 10 mg daily (dose escalation allowed) until progression or unacceptable toxicity. Null hypothesis would be rejected if more than 3 of 26 responses were observed. RESULTS: Twenty-six patients (50% were male; 6 ACC, ...
4 CitationsSource
#1Martina ImbimboH-Index: 16
#2Salvatore AlfieriH-Index: 14
Last. Paolo BossiH-Index: 39
view all 15 authors...
ObjectiveThere is no consensus on the follow-up modalities in patients with head and neck cancer. This study aims to describe the pattern and survival outcomes of recurrences/second primary cancers...
7 CitationsSource
#1Aurora Mirabile (University of Milan)H-Index: 7
#2Rosalba MiceliH-Index: 63
Last. Lisa Licitra (University of Milan)H-Index: 67
view all 10 authors...
BACKGROUND: In clinical trials of recurrent and metastatic head and neck carcinoma, Argiris et al have identified prognostic factors for overall survival (OS) and progression-free survival (PFS), weight loss, Eastern Cooperative Oncology Group performance status (ECOG-PS), tumor primary site, tumor differentiation, prior radiotherapy, deriving a two-group prognostic classification. This study evaluates Argiris's classification in "field-practice" patients. METHODS: The main analysis included 327...
2 CitationsSource
#1Francesca PlatiniH-Index: 5
#2Francesco BarrettaH-Index: 14
Last. Lisa Licitra (University of Milan)H-Index: 67
view all 15 authors...
e17537Background: CDDP is the standard of care for HNC. We performed a retrospective analysis related to baseline clinical characteristics and CDDP-nephrotoxicity in LAHNC patients (pts) treated in...
Source
#1Carlo ResteghiniH-Index: 13
#2Stefano CavalieriH-Index: 8
Last. Lisa Licitra (University of Milan)H-Index: 67
view all 14 authors...
e17530Background: Immunotherapy (IT) provides advantages in a small proportion of recurrent / metastatic head and neck squamous cell carcinoma (RM HNSCC) patients (pts). Predictive biomarkers are s...
3 CitationsSource
#1Laura D. LocatiH-Index: 31
#2Stefano CavalieriH-Index: 8
Last. Lisa LicitraH-Index: 67
view all 14 authors...
Source
#1Loris De CeccoH-Index: 23
#2M.S. SerafiniH-Index: 5
Last. Paolo BossiH-Index: 39
view all 19 authors...
Abstract Epithelial sinonasal cancers (SNCs) are rare diseases with overlapping morphological features and a dismal prognosis. We aimed to investigate the expression differences among the histological subtypes for discerning their molecular characteristics. We selected 47 SNCs: (i) 21 nonkeratinizing squamous cell carcinomas (NKSCCs), (ii) 13 sinonasal neuroendocrine cancers (SNECs), and (iii) 13 sinonasal undifferentiated cancers (SNUCs). Gene expression profiling was performed by DASL (cDNA-me...
3 CitationsSource
#1Marco Siano (HSG: University of St. Gallen)H-Index: 12
#2Salvatore AlfieriH-Index: 14
Last. Laura D. LocatiH-Index: 31
view all 7 authors...
Purpose:Two tyrosine kinase inhibitors (TKIs), vandetanib and cabozantinib, have been approved for recurrent/metastatic (R/M) medullary thyroid carcinoma (MTC). To date, it is still debated when an...
1 CitationsSource